Search the Newsreel

Cencora Raises 2026 EPS Outlook After Strong Quarter

Cencora reported strong fiscal third-quarter results, with revenue up 5.1% to $84.8 billion and adjusted diluted EPS increasing 12% to $4.48. The company subsequently raised its fiscal 2026 adjusted EPS guidance to $17.75–$17.95 and repurchased $1 billion in shares. These positive results were influenced …

ECOR Looks 25.1% Undervalued on GF Value™ Despite Revenue Miss

Cencora Inc (COR) (Q3 2026) Earnings Call Highlights: Strong Double-Digit Growth and Raised Guidance

Cencora Inc (COR) reported strong Q3 fiscal 2026 results, with double-digit adjusted operating income growth of 17% and EPS growth of 12%. The company raised its full-year fiscal 2026 adjusted EPS guidance, reflecting confidence in its performance and portfolio strength, particularly in its US …

Cencora (COR) Stock Climbs As Margin Expansion Drives Profit Momentum

Cencora (COR) stock climbed 3.6% after its latest earnings report, driven by significant margin expansion despite modest revenue growth. Adjusted operating income increased by 17% and adjusted gross profit rose by 23%, largely due to the OneOncology acquisition and a richer specialty mix. This …

Cencora (NYSE:COR) Shares Tick Up as Fiscal Q3 Results Meet Estimates, Full-Year Guidance Adjusted

Cencora (NYSE:COR) reported fiscal third-quarter results that largely met Wall Street expectations, with revenue slightly below and adjusted EPS slightly above consensus. The company also raised the lower end of its full-year adjusted profit guidance, leading to a modest positive reaction in premarket trading. …

Cencora Inc (COR) Stock Up 3.6% but GF Value Says Overvalued -- GF Score: 73/100

Cencora Inc (COR) stock rose 3.6% today, reaching $317.22, but GuruFocus's GF Value assesses it as 8.1% overvalued at $293.51. Despite this overvaluation and a high P/E ratio compared to its historical median, the company maintains above-average fundamentals with a GF Score of 73/100 …

Strong Performance From Cencora's Specialty Assets Looks Durable and Offsets Industry Headwinds

Cencora, a major player in the pharmaceutical distribution market, is showing strong performance in its specialty assets, which is helping to counteract industry challenges. The company is one of three leading domestic wholesalers, accounting for about a third of the US drug distribution market. …

Cencora, Inc. 2026: Revenue $84.75B, EPS $3.94— 10-Q Summary

Cencora, Inc. reported strong financial results for the 2026 quarter, with revenue reaching $84.75 billion, net income at $763.52 million, and diluted EPS of $3.94. This growth was fueled by increased volume in both U.S. and International segments, particularly in specialty products and GLP-1 …

Cencora Releases Q3 2026 Financial Results

Cencora (COR) announced strong Q3 2026 financial results, with adjusted EPS of $4.48, beating analyst estimates, and revenue reaching $84.75 billion, also exceeding expectations. The company saw a 5.1% year-over-year revenue increase and provided an optimistic adjusted EPS forecast for FY 2026, ranging from …

Cencora (COR) Expands Credit Facilities And Resets Receivables Terms

Cencora (COR) has revised its credit and receivables facilities, including its multi-currency revolving credit facility and receivables securitization arrangements. These changes are significant for the company's capital structure and liquidity, especially given the current challenges in the pharmaceutical and healthcare services sector. Investors should …

Cencora Expands Credit Facilities to Bolster Liquidity

Cencora (COR) has expanded its revolving credit facility to $7 billion and extended its maturity to 2031, enhancing its long-term funding capabilities. Additionally, the company amended its receivables securitization facility, reducing its base size but doubling its accordion capacity to maintain flexible liquidity. These …

Cencora Q3 2026 slides: specialty strength drives 12% EPS growth

Cencora Inc. reported strong Q3 2026 earnings, with adjusted EPS growing 12% year-over-year to $4.48 and revenue increasing 5.1% to $84.8 billion, exceeding analyst expectations. The pharmaceutical distributor raised its full-year guidance, driven by robust performance in specialty pharmaceuticals and the acquisition of OneOncology. …

Cencora (COR) Surpasses Q3 Earnings Estimates

Cencora (COR) reported strong Q3 earnings of $4.48 per share, exceeding the Zacks Consensus Estimate of $4.37. Despite missing revenue estimates slightly at $84.75 billion, the company holds a Zacks Rank #2 (Buy) due to favorable estimate revisions, suggesting potential outperformance in the near …

Cencora Inc earnings beat by $0.13, revenue topped estimates

Cencora Inc (NYSE: COR) reported strong third-quarter results, surpassing analyst estimates with an EPS of $4.48 against a $4.35 expectation and revenue of $84.8 billion against an $84.36 billion consensus. The company also provided a positive FY 2026 EPS guidance of $17.75-$17.95, which is …

Cencora shares rise 3% on beating estimates, raised guidance

Cencora Inc. (NYSE:COR) reported strong third-quarter results, exceeding analyst expectations for both earnings per share and revenue. The company also raised its full-year earnings guidance, leading to a 3.37% increase in pre-market trading. This performance was attributed to a robust pharmaceutical-centric strategy and growth …

Did Cencora Inc (COR) Exceed Expectations with Q3 EPS of $3.94 o

Earnings Flash (COR) Cencora, Inc. Posts Q3 Adjusted EPS $4.48 per Share, vs. FactSet Est of $4.35

Cencora hebt Prognose an und übertrifft Erwartungen – Aktie legt zu

Cencora raises 2026 earnings outlook after repurchasing $1B in shares

Cencora, Inc. 2026 Q3 - Results - Earnings Call Presentation (NYSE:COR) 2026-08-05

Cencora Earnings: Growth Rebound Helps Recover Some Lost Market Confidence

Cencora (NYSE: COR) director takes 97 RSUs instead of $30,000 cash retainer

Cencora director Ellen Cooper received 97 restricted stock units (RSUs) on July 31, 2026, in lieu of a $30,000 quarterly cash retainer. These RSUs, valued at $311.34 per share, increase her direct holdings to 893 shares, with the shares deferred until she leaves the …

Cencora, Inc. (NYSE: COR) grants stock to director in lieu of cash

Cencora, Inc. (NYSE: COR) director Dennis M. Nally received a grant of 113 shares of common stock on July 31, 2026, priced at $311.34 per share. This stock award, valued at $35,000, was issued in lieu of his quarterly cash retainer under the company's …

Cencora earnings up next as distribution giant eyes rebound

Cencora Inc. is set to report its fiscal third-quarter earnings, with analysts expecting $4.34 per share on $84.36 billion in revenue, reflecting a sequential revenue increase but an earnings decline. The company aims to reassure investors after missing expectations last quarter, with a focus …

FTC takes closer look at Cencora-Covetrus animal health merger, Bloomberg News reports

The U.S. Federal Trade Commission (FTC) is scrutinizing Cencora's proposed $3.5 billion acquisition of Covetrus, which would combine two major suppliers of veterinary products. The antitrust agency has sent information demands to customers and rivals of both companies to assess the deal's potential impact …

ECOR Looks 32.3% Undervalued on GF Value™ Amid Price-to-Sales Co

Cencora to Report Q3 Earnings: Is a Beat Likely for the Stock?

Cencora (COR) is poised to report its third-quarter fiscal 2026 results on August 5th, with analysts predicting revenue of $84.89 billion and earnings of $4.37 per share. The company has a history of beating earnings estimates and is expected to deliver another quarter of …

Kultura Brands Reports Strong Commercial Momentum Following Successful Participation at Cencora ThoughtSpot 2026

Kultura Brands, Inc. announced strong commercial momentum following its successful participation at Cencora ThoughtSpot 2026, an event for independent pharmacies. The company strengthened strategic relationships, expanded its commercial pipeline, and received positive feedback for its "Thirst Responder" product. Kultura Brands plans to continue developing …

Kincora Copper Limited (KCC.XA) recent insider transactions

Cencora (COR) Stock May Be 38% Undervalued As Cash Flow Holds Up

Cencora (COR) stock appears to be significantly undervalued, trading at a 38% discount to its estimated intrinsic value according to a Discounted Cash Flow (DCF) model, and also showing as undervalued based on its P/E ratio compared to industry averages. Despite strong long-term returns, …

XS307124637 Bond Profile — Key Metrics

This article provides a detailed profile of the XS307124637 bond issued by Cencora, Inc., outlining key metrics such as its coupon rate of 3.63%, maturity date of May 22, 2032, and an outstanding amount of 500 million EUR. It also includes a description of …

Net debt of Cencora, Inc. – HAM:ABG

This article provides financial information for Cencora, Inc. (HAM:ABG) focusing on its net debt. It specifies that the market is closed with no trades and gives an overview of available financial data. The content primarily comes from TradingView, referencing various data providers.

Price to cash flow ratio of Cencora, Inc. – HAM:ABG

This article provides financial information for Cencora, Inc. (HAM:ABG) on TradingView, specifically focusing on its price-to-cash-flow ratio. It indicates that the market is currently closed with no trades, and offers various tools and resources available on the TradingView platform for financial analysis.

Announcement of the total number of voting rights as at 31 July 2026

KBC Ancora Regulated information, Leuven, 31 July 2026 (17.40 hrs CEST) Announcement of the total number of voting rights as at 31 July 2026 In application of Article 15 of the Act of 2 May 2007 on the disclosure of major shareholdings in issuers …

ABC5748091 Bond Risk Profile

This page provides a detailed profile for the Cencora, Inc. 5.125% 15-FEB-2034 bond (ABC5748091), including an overview of its coupon, redemption, and risks. It highlights key metrics for credit risk assessment, such as security level, inflation protection, and issuer rating, to help users evaluate …

Countdown to Cencora (COR) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS